$0.5603
-0.0988-14.99%
Últ. Act.: Oct 30, 4:58 PM
Aldeyra Therapeutics (ALDX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.08 | $-0.12 | $-0.12 | $-0.17 |
| Actual | $-0.09 | $-0.06 | $-0.10 | $-0.13 |
| Surprise | -12.5% | +50.0% | +16.7% | +23.5% |
| Revenue | ||||
| Estimate | $47.0M | $47.0M | $24.3M | $24.3M |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | -100.0% | -100.0% | -100.0% | -100.0% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.10 | $-0.10 |
| Revenue | ||
| Consensus | $1.0M | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.09 | $-0.08 | -12.5 % |
| Q1 | May 7, 2026 | $-0.06 | $-0.12 | 50.0 % |
| Q4 | Feb 27, 2026 | $-0.10 | $-0.12 | 16.7 % |
| Q3 | Nov 5, 2025 | $-0.13 | $-0.17 | 23.5 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $0 | $47.00M | -100.0 % |
| Q1 | May 7, 2026 | $0 | $47.00M | -100.0 % |
| Q4 | Feb 27, 2026 | $0 | $24.25M | -100.0 % |
| Q3 | Nov 5, 2025 | $0 | $24.25M | -100.0 % |